Office Locations:

890 Winter Street, Suite 110
Waltham, MA 02451
Phone: 781-472-2740
Fax: 781-472-2642

Get all office locations for this firm with a National Database subscription.


  • Early



  • Life Sciences & Healthcare
  • Medical Device



    LSP is one of Europe's largest and most experienced healthcare investment firms. The firm has raised more than EURO1.7 billion through various funds that target drug development and medical technology. Currently LSP manages three different fund types: LSP 6, a closed-end private equity fund investing in early-to late stage drug development and medical technology companies; LSP HEF 2 (Health Economic Fund), a closed-end private equity fund investing in late-stage medical technology companies with a health and economic benefit; and LSP Public, an open-ended fund investing in healthcare companies listed on a stock exchange. The fund itself is listed on Euronext as LSP Life Sciences Fund with ticker LSP NA and ISIN Code NL0009756394.

    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Growth Stage
    (also called Mid-stage)
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B

    Investment Team:

    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Dr Rene Kuijten Managing Partner
    Fouad Azzam General Partner
    Joachim (JR) Rothe Managing Partner
    Mark Wegter Managing Partner
    Martijn Kleijwegt Managing Partner


    Recent Funding Events (trailing 12 months):















      Series D


    Portfolio companies include:

        web link

        web link


    Recent News: